ES2089027T3 - Forma de dosificacion transmucosica. - Google Patents

Forma de dosificacion transmucosica.

Info

Publication number
ES2089027T3
ES2089027T3 ES90913359T ES90913359T ES2089027T3 ES 2089027 T3 ES2089027 T3 ES 2089027T3 ES 90913359 T ES90913359 T ES 90913359T ES 90913359 T ES90913359 T ES 90913359T ES 2089027 T3 ES2089027 T3 ES 2089027T3
Authority
ES
Spain
Prior art keywords
drug
mouth
absorption
methods
mucosal tissues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90913359T
Other languages
English (en)
Inventor
Theodore H Stanley
Brian Hague
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation UURF
Original Assignee
University of Utah Research Foundation UURF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation UURF filed Critical University of Utah Research Foundation UURF
Application granted granted Critical
Publication of ES2089027T3 publication Critical patent/ES2089027T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/50—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by shape, structure or physical form, e.g. products with supported structure
    • A23G3/54—Composite products, e.g. layered, coated, filled
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/50—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by shape, structure or physical form, e.g. products with supported structure
    • A23G3/56—Products with edible or inedible supports, e.g. lollipops
    • A23G3/563—Products with edible or inedible supports, e.g. lollipops products with an inedible support, e.g. a stick
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015—Devices specially adapted for taking medicines
    • A61J7/003—Sticks, e.g. lollipops with drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSICIONES Y METODOS DE FABRICACION PARA PRODUCIR UNA COMPOSICION MEDICINAL CAPAZ DE SER ABSORBIDA A TRAVES DE LOS TEJIDOS MUCOSOS DE LA BOCA, FARINGE Y ESOFAGO. ESTA INVENCION DESCRIBE LAS COMPOSICIONES Y METODOS QUE SON UTILES EN LA ADMINISTRACION DE MEDICAMENTOS LIPOFILICOS Y NOLIPOFILICOS DE UNA MANERA DOSIS A EFECTO TAL QUE SE ADMINISTRE SUFICIENTE MEDICAMENTO PARA PRODUCIR CON PRECISION UN EFECTO DESEADO. LA INVENCION DESCRIBE TAMBIEN TECNICAS DE FABRICACION QUE PERMITE INCORPORAR AGENTES TERAPEUTICOS (30) EN MATRICES DE CONTENIDO DE MEDICAMENTOS INDISOLUBLES (34) QUE SON CAPACES DE LIBERAR EL MEDICAMENTO DENTRO DE LA BOCA DE UN PACIENTE. HAY UN APARATO O SUJETADOR (36) PREFERENTEMENTE UNIDO A LA MATRIZ QUE CONTIENE EL MEDICAMENTO (34). EMPLEANDO ESTA INVENCION EL MEDICAMENTO (30) SE PUEDE INTRODUCIR EN LA CORRIENTE SANGUINEA DEL PACIENTE CASI TAN DEPRISA COMO A TRAVES DE UNA INYECCION, Y MUCHO MAS DEPRISA QUE UTILIZANDO LA RUTA DE ADMINISTRACION ORAL, MIENTRAS QUE SE EVITAN LOS ASPECTOS NEGATIVOS DE AMBOS METODOS. LA MATRIZ QUE CONTIENE EL MEDICAMENTO INDISOLUBLE (34) PUEDE INCLUIR REALZADORES DE PERMEABILIDAD PARA INCREMENTAR LA ABSORCION DEL MEDICAMENTO POR LOS TEJIDOS MUCOSOS DE LA BOCA. LA COMPOSICION DE LA MATRIZ (34) PUEDE INCLUIR TAMBIEN AGENTES TAMPONES PH PARA MODIFICAR EL PH DE LA SALIVA, INCREMENTANDO ASI LA ABSORCION DEL MEDICAMENTO (30) A TRAVES DE LOS TEJIDOS MUCOSOS.
ES90913359T 1989-09-05 1990-08-03 Forma de dosificacion transmucosica. Expired - Lifetime ES2089027T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/403,752 US5288498A (en) 1985-05-01 1989-09-05 Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments

Publications (1)

Publication Number Publication Date
ES2089027T3 true ES2089027T3 (es) 1996-10-01

Family

ID=23596874

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90913359T Expired - Lifetime ES2089027T3 (es) 1989-09-05 1990-08-03 Forma de dosificacion transmucosica.

Country Status (11)

Country Link
US (1) US5288498A (es)
EP (1) EP0490944B1 (es)
JP (1) JP2749198B2 (es)
AT (1) ATE138562T1 (es)
AU (1) AU642664B2 (es)
CA (1) CA2066403C (es)
DE (1) DE69027216T2 (es)
DK (1) DK0490944T3 (es)
ES (1) ES2089027T3 (es)
NO (1) NO920858D0 (es)
WO (1) WO1991003236A1 (es)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824334A (en) * 1989-09-05 1998-10-20 University Of Utah Research Foundation Tobacco substitute
GB9212511D0 (en) * 1992-06-12 1992-07-22 Cortecs Ltd Pharmaceutical compositions
DE4314976C1 (de) * 1993-05-06 1994-10-06 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme zur Verabreichung von Wirkstoffen, Verfahren zu ihrer Herstellung und ihre Verwendung
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
WO1995003771A1 (en) * 1993-08-03 1995-02-09 Pacific Rim Productions Pty. Ltd. Treatment of oral ailments
US5679714A (en) * 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
WO1996000072A1 (en) * 1994-06-23 1996-01-04 The Procter & Gamble Company Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine
US5705183A (en) * 1994-11-16 1998-01-06 Phillips Company Cotton candy coated medication and a method for making and administering the same
CN1088580C (zh) 1994-12-22 2002-08-07 阿斯特拉公司 气溶胶药物制剂
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
EP0806945B1 (en) * 1994-12-22 2003-04-23 AstraZeneca AB Therapeutic preparation for inhalation containing parathyro d hormone, pth
EP0814790B1 (en) * 1995-02-24 2003-07-16 Stuart L. Weg Administration of ketamine for detoxification
AU4988696A (en) * 1995-03-29 1996-10-16 Procter & Gamble Company, The Antitussive microcapsules
SE9601421D0 (sv) * 1996-04-12 1996-04-12 Astra Ab New composition
US5726154A (en) * 1996-06-28 1998-03-10 University Of Utah Research Foundation Stabilization and oral delivery of calcitonin
CA2259418A1 (en) * 1996-07-11 1998-01-22 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
DE19645044A1 (de) * 1996-10-31 1998-05-07 Falk Pharma Gmbh Verwendung von Ursodeoxycholsäure zur topischen Behandlung von Entzündungserkrankungen der Schleimhäute
AU5523298A (en) * 1996-12-20 1998-07-17 Marcel E. Nimni Novel topical formulation of anti-inflammatory drugs for the treatment of localized pain
US20040023948A1 (en) * 1997-03-24 2004-02-05 Green Richard David Fast-dispersing dosage form containing 5-HT1 agonists
US5762494A (en) * 1997-03-24 1998-06-09 Archambault; Gregory A. Applicator device and method
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US20020018754A1 (en) * 1999-03-15 2002-02-14 Paul Albert Sagel Shapes for tooth whitening strips
US6096328A (en) * 1997-06-06 2000-08-01 The Procter & Gamble Company Delivery system for an oral care substance using a strip of material having low flexural stiffness
US6197331B1 (en) 1997-07-24 2001-03-06 Perio Products Ltd. Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity
GB9717770D0 (en) * 1997-08-21 1997-10-29 Scherer Ltd R P Pharmaceutical composition
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
WO1999034751A1 (en) 1998-01-06 1999-07-15 Sceusa Nicholas A A drug dosage form based on the teorell-meyer gradient
EP1075278A1 (en) * 1998-01-13 2001-02-14 AstraZeneca UK Limited PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D 2?) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING $g(b) 2?-ADRENORECEPTOR AGONIST ACTIVITY
US7022683B1 (en) * 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
WO2000010531A1 (en) * 1998-08-19 2000-03-02 Rtp Pharma Inc. Injectable aqueous dispersions of propofol
US6358060B2 (en) 1998-09-03 2002-03-19 Jsr Llc Two-stage transmucosal medicine delivery system for symptom relief
US6344222B1 (en) 1998-09-03 2002-02-05 Jsr Llc Medicated chewing gum delivery system for nicotine
US20020098264A1 (en) * 1998-11-27 2002-07-25 Cherukuri Subraman R. Medicated chewing gum delivery system for nicotine
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
MXPA01007024A (es) 1999-01-08 2002-03-27 B Bacaner Marvin Composiciones y equipos novedosos de bretilio y su uso en la prevencion y el tratamiento de condiciones cardiovasculares.
US6884792B2 (en) * 1999-01-08 2005-04-26 Marvin B. Bacaner Bretylium compositions and kits and their use in preventing and treating cardiovascular conditions
WO2000047203A1 (en) * 1999-02-12 2000-08-17 Mqs, Inc. Formulation and system for intra-oral delivery of pharmaceutical agents
EP1200064B1 (en) 1999-07-02 2003-05-02 The Procter & Gamble Company Delivery system for oral care compositions comprising organosiloxane reins using a removable backing strip
WO2001013900A2 (en) 1999-08-24 2001-03-01 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
AU2001261744A1 (en) * 2000-05-19 2001-12-03 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
WO2002013781A1 (en) * 2000-08-14 2002-02-21 Fertin Pharma A/S Method for preparation of chewing gum with customer acceptable taste
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
US20020160043A1 (en) * 2001-02-27 2002-10-31 Dennis Coleman Compositions and method of manufacture for oral dissolvable dosage forms
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
EP1386251A4 (en) * 2001-03-02 2005-11-23 Euro Celtique Sa METHOD AND DEVICE FOR COMPACTING INDIVIDUALIZED DOSAGE FORMS
BR0207930A (pt) * 2001-03-05 2004-03-02 Ortho Mcneil Pharm Inc Composições farmacêuticas lìquidas com sabor mascarado
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
JP2005508888A (ja) * 2001-08-14 2005-04-07 バイオティ セラピーズ コーポレイション アルコール依存症またはアルコール中毒を治療する方法
DE10141650C1 (de) * 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US6949240B2 (en) * 2002-05-23 2005-09-27 The Procter & Gamble Company Tooth whitening products
US8524200B2 (en) 2002-09-11 2013-09-03 The Procter & Gamble Company Tooth whitening products
US20050019277A1 (en) * 2002-09-11 2005-01-27 The Procter & Gamble Company Tooth whitening products
AU2003266159A1 (en) * 2002-09-16 2004-04-30 Zicam, Llc. System and method for delivering a composition to the nasal membrane
US20040131662A1 (en) 2003-11-12 2004-07-08 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
US9561182B2 (en) * 2003-08-22 2017-02-07 Cure Pharmaceutical Corporation Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
US8999372B2 (en) * 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
US20040191302A1 (en) 2003-03-28 2004-09-30 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
US20040115244A1 (en) * 2002-12-17 2004-06-17 Holgate Eric Jamison Methods and compositions for nicotine replacement therapy
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
US20040253307A1 (en) * 2003-02-04 2004-12-16 Brian Hague Sugar-free oral transmucosal solid dosage forms and uses thereof
US7648982B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
US7648981B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en) * 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US20050037040A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of urea and ammonium lactate
US20050036953A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of ammonium lactate
US20050042182A1 (en) * 2003-08-13 2005-02-24 Moshe Arkin Topical compositions of urea
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050025833A1 (en) * 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
PL1648421T3 (pl) 2003-07-24 2018-03-30 Glaxosmithkline Llc Folie rozpuszczające się w jamie ustnej
US20050042281A1 (en) * 2003-08-21 2005-02-24 Singh Nikhilesh N. Compositions for delivering therapeutic agents across the oral mucosa
US8627828B2 (en) * 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
CN104397869B (zh) 2003-11-07 2016-06-08 美国无烟烟草有限责任公司 烟草组合物
EP1715853A4 (en) * 2004-02-17 2012-07-18 Transcept Pharmaceuticals Inc COMPOSITIONS FOR THE DISTRIBUTION OF HYPNOTICS IN THE FIELD OF MUNICHCHLEIMHÄUTE AND USE METHOD THEREOF
US7161034B2 (en) * 2004-04-20 2007-01-09 Dade Behring Inc. Lidocaine analogs and methods of making and using same
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
ES2660172T3 (es) * 2004-05-19 2018-03-21 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Composición inyectable que comprende desoxicolato de sodio
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
CA2569964A1 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
US20060004035A1 (en) * 2004-06-25 2006-01-05 Cephalon, Inc. System for identification of a pharmaceutical product
US20060051413A1 (en) * 2004-09-08 2006-03-09 Chow Sing S M Method of enhancing absorptions of transmucosal administration formulations
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US8242131B2 (en) * 2005-05-25 2012-08-14 Transcept Pharmaceuticals, Inc. Methods of treating middle-of-the-night insomnia
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US9066847B2 (en) * 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US9289583B2 (en) * 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US20070260491A1 (en) * 2006-05-08 2007-11-08 Pamela Palmer System for delivery and monitoring of administration of controlled substances
US20070299687A1 (en) * 2006-06-23 2007-12-27 Pamela Palmer Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
US8642016B2 (en) * 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
KR101230804B1 (ko) 2006-07-21 2013-02-08 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 향상된 흡수를 갖는 경점막 전달 장치
US8158609B1 (en) 2006-11-02 2012-04-17 Novartis Ag Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
US20080131508A1 (en) * 2006-12-01 2008-06-05 Cephalon, Inc Oral transmucosal nicotine dosage form
US20090214442A1 (en) * 2006-12-01 2009-08-27 Cephalon, Inc. Oral Transmucosal Nicotine Dosage Form
WO2008091588A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
US8481084B2 (en) 2007-05-23 2013-07-09 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
CA2716835A1 (en) 2008-02-27 2009-09-03 Amcol International Corporation Methods of treating cardiovascular disorders associated with atherosclerosis
WO2009148442A1 (en) 2008-06-04 2009-12-10 Colgate-Palmolive Company Oral care implement with cavitation system
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
US9211282B2 (en) 2009-09-25 2015-12-15 Dr. Reddy's Laboratories Ltd. Formulations comprising triptan compounds
US20110282248A1 (en) 2010-03-04 2011-11-17 Martin Ruth E Portable high frequency air pulse delivery device
WO2012112940A1 (en) 2011-02-18 2012-08-23 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
US20150057517A1 (en) * 2012-03-27 2015-02-26 University Of Utah Research Foundation Sample capture device and systems and methods of using same
WO2013144710A1 (en) 2012-03-29 2013-10-03 Trudell Medical International Oral device with bolus simulator and method of use thereof
WO2013173716A2 (en) 2012-05-18 2013-11-21 University Of Utah Research Foundation Methods for diagnosing and monitoring eosinophilic esophagitis
US10285915B2 (en) 2012-10-17 2019-05-14 The Procter & Gamble Company Strip for the delivery of an oral care active and methods for applying oral care actives
US20160000702A1 (en) * 2013-02-22 2016-01-07 Eastgate Pharmaceuticals Inc. Pharmaceutical composition for enhanced transmucosal adminstration of benzodiazepines
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
BR112017024356A2 (pt) * 2015-05-13 2018-07-31 Monopar Therapeutics Inc clonidina e/ou derivados de clonidina para uso na prevenção de lesão na pele resultante de radioterapia
JP6868027B2 (ja) 2015-12-09 2021-05-12 トゥルーデル メディカル インターナショナル 口腔器具、組立体およびその使用方法
USD838368S1 (en) 2015-12-09 2019-01-15 Trudell Medical International Oral device
US20170319832A1 (en) * 2016-05-09 2017-11-09 Kelly Gardner Devices for hydrating patients
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
JP6671616B2 (ja) * 2017-11-02 2020-03-25 コスメディ製薬株式会社 歯科用局所麻酔マイクロニードルアレイ
PL428534A1 (pl) * 2019-01-10 2020-07-13 Biotts Spółka Akcyjna Nośnik farmaceutyczny dla substancji czynnych oraz kompozycja farmaceutyczna ją zawierająca
KR102458445B1 (ko) * 2020-01-29 2022-10-24 박기원 반려동물용 다기능 미세 영양캡슐 제조방법 및 그 방법에 의해 제조된 반려동물용 미세 영양캡슐
US20230210159A1 (en) * 2022-01-05 2023-07-06 Ava Jackson Flavor Delivery Device

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US122507A (en) * 1872-01-02 Improvement in medical compounds or worm-candies
US2963404A (en) * 1958-09-05 1960-12-06 Pfizer & Co C Tannate candy making, and product
US3556811A (en) * 1969-08-11 1971-01-19 Walton J Smith Low-fermentability hard candy
US3697641A (en) * 1970-01-02 1972-10-10 Gerhard W Ahrens Nonhygroscopic non-sugarbase noncariogenic-vitamin c releasable base material for use in the preparation of suckable tablets,lozenges and chocolate
US3622352A (en) * 1970-04-30 1971-11-23 Philip Morris Inc Edible compositions and method for coating them
US4207890A (en) * 1977-01-04 1980-06-17 Mcneilab, Inc. Drug-dispensing device and method
WO1985000372A1 (fr) * 1983-07-01 1985-01-31 Battelle Memorial Institute Polypeptide biodegradable et son utilisation pour le relargage progressif de medicaments
US4642231A (en) * 1983-07-20 1987-02-10 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates of antihistamines
US4749575A (en) * 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
US4551329A (en) * 1984-01-20 1985-11-05 Joan Harris Oral medicament lollipop
US4863737A (en) * 1985-05-01 1989-09-05 University Of Utah Compositions and methods of manufacture of compressed powder medicaments
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4818539A (en) * 1985-02-05 1989-04-04 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
DE3809236A1 (de) * 1988-03-18 1989-09-28 Lohmann Therapie Syst Lts Verwendung von ketogruppenhaltigen zyklischen verbindungen

Also Published As

Publication number Publication date
ATE138562T1 (de) 1996-06-15
DK0490944T3 (da) 1996-10-21
CA2066403C (en) 1998-04-14
AU6337190A (en) 1991-04-08
US5288498A (en) 1994-02-22
DE69027216T2 (de) 1996-10-17
CA2066403A1 (en) 1991-03-06
JP2749198B2 (ja) 1998-05-13
DE69027216D1 (de) 1996-07-04
JPH05500058A (ja) 1993-01-14
AU642664B2 (en) 1993-10-28
WO1991003236A1 (en) 1991-03-21
NO920858L (no) 1992-03-04
EP0490944A1 (en) 1992-06-24
EP0490944A4 (en) 1992-08-05
NO920858D0 (no) 1992-03-04
EP0490944B1 (en) 1996-05-29

Similar Documents

Publication Publication Date Title
ES2089027T3 (es) Forma de dosificacion transmucosica.
DK0491778T3 (da) Indretning til administration af medikamenter til slimhindevæv.
ATE94393T1 (de) Dosisform zur oralen verabreichung des hypoglykaemischen glipizids.
KR920703018A (ko) 약학 조성물과 그 투약기구
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
RU2002127804A (ru) Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
HK1050313A1 (en) Oral transmucosal drug dosage using solid solution
KR950703951A (ko) 광학적으로 순수한 r-케토로락을 포함하는 조성물과 무통과 해열치료에 이를 사용하는 방법(antipyretic and analgesic methods and compositions containing optically pure r-ketorolac)
MXPA05012810A (es) Formas de dosis oral de memantina.
ES469878A1 (es) Un procedimiento para preparar una composicion farmaceutica para el tratamiento del habito de consumir drogas
RU2002122084A (ru) Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных растройств
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
JP2002544227A5 (es)
JP2003514025A5 (es)
JP2002540148A5 (es)
JP2002530353A5 (es)
RU2002124141A (ru) Применение миртазапина для лечения расстройств сна
AR006202A1 (es) Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene
RU2002129298A (ru) Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера
ATE301452T1 (de) Verfahren zur herstellung einer flüssigen dosierungseinheit und kit
KR930702985A (ko) 식도암의 치료
US2830930A (en) Parenteral dental local anesthetic solutions containing an alkantheline
RU2002126216A (ru) Фармацевтическая композиция для лечения и профилактики фиброза и цирроза печени
Shochat et al. Preanesthetic suppository for ambulatory children: Importance of the base

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 490944

Country of ref document: ES

FG2A Definitive protection

Ref document number: 490944

Country of ref document: ES